arrow
J

Jean-Philippe Metges

chu brest
H指数:29
被引数:6,877

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study

帕博利珠单抗联合化疗与化疗对比治疗晚期食管癌:KEYNOTE-590随机III期研究的5年扩展随访

2025-11-180
OAAI
Proposals to develop innovation and research in cancer and optimize care for patients affected by cancer

关于发展癌症领域创新与研究的提案,以及优化受癌症影响患者的护理方案。

2025-09-010
PRE
Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial)

基于贝伐珠单抗的化疗,根据贝伐珠单抗药代动力学适应性调整,用于不可切除性转移性结直肠癌患者的一线治疗:一项双盲、多中心、随机III期临床试验研究(PHARBEVACOL试验)

2025-05-010
OAAI
Resection of colorectal liver metastases with second-line aflibercept plus FOLFIRI: Results from the RESECTION prospective French cohort
2024-12-010
PRE
A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer
2024-08-081
OAAI
Effect of Adapted Physical Activity in Patients With Advanced Pancreatic Cancer: The APACaP GERCOR Randomized Trial
2023-12-013
OA
Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial
2022-02-0133
PRE
Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival
2021-12-1026
OAAI
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
LANCET
IF88.5
2021-08-01866
PREAI
Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial

durvalumab,tremelimumab和紫杉醇在胆道癌中的三联组合: IMMUNOBIL PRODIGE 57 II期随机试验的安全性运行结果

2021-01-0134
OAAI
Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27)
2020-12-0112
OAAI